Highlights
The Evaluating Liraglutide in Alzheimer’s Disease (ELAD) phase 2b trial found no significant difference in the primary endpoint of cerebral glucose metabolic rate between liraglutide and placebo groups over 52 weeks. Secondary endpoints revealed a statistically significant benefit in the Alzheimer’s Disease Assessment Scale-Executive domain (ADAS-Exec) for patients treated with liraglutide. Liraglutide demonstrated a favorable safety profile in non-diabetic patients with Alzheimer’s disease, consistent with its known clinical profile in metabolic medicine. The study underscores the complexity of using metabolic markers as proxies for clinical cognitive outcomes in neurodegenerative research.
Background: The Metabolic Intersection of Neurodegeneration
Alzheimer’s disease (AD) is increasingly recognized not only as a proteinopathy involving amyloid-beta and tau but also as a condition characterized by significant metabolic dysfunction. Often colloquially referred to as type 3 diabetes, AD involves impaired insulin signaling and glucose utilization in the brain, which correlates with cognitive decline and synaptic loss. Glucagon-like peptide 1 (GLP-1) receptor agonists, long established as cornerstones in the management of type 2 diabetes and obesity, have emerged as promising neuroprotective candidates. Preclinical models have demonstrated that GLP-1 agonists can cross the blood-brain barrier, reduce neuroinflammation, decrease amyloid plaque accumulation, and enhance synaptic plasticity. Given these findings, the ELAD trial was designed to bridge the gap between animal models and clinical application, specifically targeting patients with mild-to-moderate AD syndrome.
The ELAD Trial: Study Design and Methodology
The Evaluating Liraglutide in Alzheimer’s Disease (ELAD) study was a multicenter, randomized, double-blind, placebo-controlled phase 2b trial. The trial recruited 204 participants across multiple clinical sites who met the criteria for mild-to-moderate Alzheimer’s disease. Crucially, participants were excluded if they had a diagnosis of diabetes, ensuring that any observed effects were independent of the drug’s systemic glucose-lowering properties. Participants were randomized to receive either a daily subcutaneous injection of liraglutide (titrated to 1.8 mg) or a matching placebo for a duration of 52 weeks. The investigation employed a sophisticated battery of biomarkers and clinical assessments. The primary outcome was the change in cerebral glucose metabolic rate (CMRglu) measured via 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) in several regions of interest. Secondary outcomes included safety, tolerability, and a range of neuropsychometric evaluations such as the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), the Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL), and the Clinical Dementia Rating-Sum of Boxes (CDR-SoB).
Primary Results: Cerebral Glucose Metabolism
The primary analysis of the ELAD trial focused on whether liraglutide could preserve or enhance cerebral glucose metabolism, a marker often diminished in AD patients. At the end of the 52-week treatment period, the results showed no significant difference in CMRglu between the liraglutide group and the placebo group. The reported difference was -0.17 with a 95% confidence interval (CI) ranging from -0.39 to 0.06 (P = 0.14). This finding was unexpected given the metabolic hypothesis and preclinical evidence suggesting that GLP-1 agonists might stabilize brain metabolism. The lack of significance in the primary endpoint suggests that either the 52-week duration was insufficient to observe metabolic shifts or that FDG-PET may not be the most sensitive biomarker for the specific neuroprotective actions of liraglutide in this population.
Secondary Outcomes: Cognitive and Functional Performance
Despite the neutral primary endpoint, the secondary outcomes provided intriguing signals regarding cognitive preservation. Most notably, the Alzheimer’s Disease Assessment Scale-Executive domain (ADAS-Exec) showed a statistically significant advantage for the liraglutide-treated group compared to the placebo (difference = 0.15; 95% CI: 0.03-0.28; unadjusted P = 0.01). Executive function, which involves higher-level cognitive processes such as planning and problem-solving, is often severely impacted in the progression of AD. However, other global measures of cognition and function did not reach statistical significance. The Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) showed a difference of -0.58 (95% CI: -3.13 to 1.97; unadjusted P = 0.65), and the Clinical Dementia Rating-Sum of Boxes (CDR-SoB) showed a difference of -0.06 (95% CI: -0.57 to 0.44; unadjusted P = 0.81). These results suggest that while liraglutide may exert specific effects on certain cognitive domains, its impact on overall functional status in a 12-month window remains modest.
Safety and Tolerability in a Non-Diabetic Population
A key concern in repurposing metabolic drugs for neurology is the safety profile in patients without the target metabolic condition. The ELAD trial confirmed that liraglutide was generally safe and well-tolerated in non-diabetic AD patients. The adverse events observed were consistent with the known side effects of GLP-1 agonists, primarily gastrointestinal in nature (e.g., nausea, vomiting, and decreased appetite). There were no significant increases in severe hypoglycemia or other metabolic emergencies, which is vital for the long-term feasibility of using these agents in an elderly population often burdened by polypharmacy.
Clinical Implications and Expert Commentary
The ELAD trial represents a critical step in the exploration of the metabolic-cognitive axis. The discrepancy between the primary metabolic endpoint and the secondary executive function benefit highlights the challenges of biomarker selection in AD trials. Some experts argue that the FDG-PET metabolic rate might be too distal a marker for the immediate neuroprotective effects of incretin therapies. The positive signal in the ADAS-Exec domain is particularly noteworthy. Executive dysfunction is a major driver of caregiver burden and loss of independence. If GLP-1 agonists can specifically target the frontal-striatal circuits responsible for these functions, they could provide a valuable adjunct to amyloid-targeting therapies. However, caution is warranted. The P-value for the secondary cognitive outcome was unadjusted for multiple comparisons, increasing the risk of a type I error. Furthermore, the lack of movement in ADCS-ADL and CDR-SoB indicates that the observed cognitive benefit did not yet translate into a perceptible change in daily functioning or disease staging during the study timeframe.
Conclusion: A Stepping Stone for Incretin-Based Neurotherapeutics
The ELAD trial provides a nuanced conclusion to the study of liraglutide in Alzheimer’s disease. While it did not meet its primary objective of altering cerebral glucose metabolism, the evidence of executive function preservation and a clean safety profile keeps the GLP-1 hypothesis alive. These findings have already paved the way for larger, more definitive trials, such as the ongoing investigations into semaglutide (a more potent, long-acting GLP-1 agonist) in early AD. For clinicians, the ELAD trial serves as a reminder that the path to a multi-modal treatment strategy for Alzheimer’s—one that addresses amyloid, tau, and metabolism—is complex but progressing. Future research should focus on longer follow-up periods and perhaps more sensitive imaging markers, such as functional MRI or specific markers of neuroinflammation, to fully elucidate the therapeutic potential of GLP-1 agonists.
Funding and ClinicalTrials.gov
The ELAD trial was supported by various research grants and institutional funding. The study is registered at ClinicalTrials.gov with the identifier NCT01843075.
References
1. Edison P, Femminella GD, Ritchie C, et al. Liraglutide in mild to moderate Alzheimer’s disease: a phase 2b clinical trial. Nat Med. 2026 Jan;32(1):353-361. doi: 10.1038/s41591-025-04106-7. 2. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-1439. 3. De Felice FG, Lourenco MV, Ferreira ST. How does brain insulin resistance develop in Alzheimer’s disease? Alzheimer’s Dement. 2014;10(1 Suppl):S26-S32. 4. Grieco M, et al. Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases. Front Neurosci. 2019;13:1112.